Skip to main content
Top

ESMO 2025: The KEYNOTE-905 trial

Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus pembrolizumab as a new option for cisplatin-ineligible muscle-invasive bladder cancer. 

More from ESMO Congress 2025

Image Credits
Christof Vulsteke/© Springer Medicine, Woman receiving an intravenous infusion/© FatCamera / Getty Images / iStock (symbolic image with model), Erica Mayer/© Springer Medicine, Jeanne Tie/© Springer Medicine, DNA testing of blood - conceptual/© blindturtle / stock.adobe.com